Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 158,600 shares, a drop of 21.7% from the February 28th total of 202,600 shares. Based on an average trading volume of 377,700 shares, the days-to-cover ratio is presently 0.4 days. Currently, 3.9% of the company’s stock are sold short.

Institutional Investors Weigh In On Virax Biolabs Group

An institutional investor recently bought a new position in Virax Biolabs Group stock. XTX Topco Ltd bought a new position in Virax Biolabs Group Limited (NASDAQ:VRAX) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 11,863 shares of the company’s stock, valued at approximately $27,000. XTX Topco Ltd owned approximately 0.37% of Virax Biolabs Group as of its most recent SEC filing. 8.61% of the stock is currently owned by institutional investors.

Virax Biolabs Group Stock Down 6.5 %

Shares of Virax Biolabs Group stock opened at $1.16 on Monday. Virax Biolabs Group has a 52-week low of $0.60 and a 52-week high of $9.00. The firm’s 50 day moving average price is $1.65 and its 200-day moving average price is $1.91.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.